Radar-Guided Localization and Resection for Metastatic Nodal and Soft Tissue Melanoma: A Single-Institution Retrospective Study.

Autor:	Beekman KE; USF Health Morsani College of Medicine, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., DePalo DK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Parker LM; USF Health Morsani College of Medicine, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Elleson KM; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Mullinax JE; Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA.; Department of Oncologic Sciences, USF Health Morsani College of Medicine, Tampa, FL, USA., Sarnaik AA; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Oncologic Sciences, USF Health Morsani College of Medicine, Tampa, FL, USA., Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Oncologic Sciences, USF Health Morsani College of Medicine, Tampa, FL, USA., Zager JS; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Oncologic Sciences, USF Health Morsani College of Medicine, Tampa, FL, USA.
Jazyk:	angličtina
Zdroj:	Cancer control : journal of the Moffitt Cancer Center [Cancer Control] 2024 Jan-Dec; Vol. 31, pp. 10732748241237907.
DOI:	10.1177/10732748241237907
Abstrakt:	Background: Radar-guided localization (RGL) offers a wire-free, nonradioactive surgical guidance method consisting of a small percutaneously-placed radar reflector and handheld probe. This study investigates the feasibility, timing, and outcomes of RGL for melanoma metastasectomy. Methods: We retrospectively identified patients at our cancer center who underwent RGL resection of metastatic melanoma between December 2020-June 2023. Data pertaining to patients' melanoma history, management, reflector placement and retrieval, and follow-up was extracted from patient charts and analyzed using descriptive statistics. Results: Twenty-three RGL cases were performed in patients with stage III-IV locoregional or oligometastatic disease, 10 of whom had reflectors placed prior to neoadjuvant therapy. Procedures included soft tissue nodule removals (8), index lymph node removals (13), and therapeutic lymph node dissections (2). Reflectors were located and retrieved intraoperatively in 96% of cases from a range of 2 to 282 days after placement; the last reflector was not able to be located during surgery via probe or intraoperative ultrasound. One retrieved reflector had migrated from the index lesion, thus overall success rate of reflector and associated index lesion removal was 21 of 23 (91%). All RGL-localized and retrieved index lesions that contained viable tumor (10) had microscopically negative margins. There were no complications attributable to reflector insertion and no unexpected complications of RGL surgery. Conclusion: In our practice, RGL is a safe and effective surgical localization method for soft tissue and nodal melanoma metastases. The inert nature of the reflector enables implantation prior to neoadjuvant therapy with utility in index lymph node removal. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Amod A Sarnaik is a co-inventor on a patent application with Provectus Biopharmaceuticals. Dr Sarnaik has received consulting fees from Iovance Biotherapeutics, Guidepoint, Defined Health, Huron Consulting Group, KeyQuest Health Inc, Istari, Rising Tide, and Gerson Lehrman Group. Dr Sarnaik has received speaker fees from the Society for Immunotherapy of Cancer, Physicians’ Educational Resource (PER) LLC, Medscape, and Medstar Health. Vernon K Sondak serves in a consulting or advisory role for Merck/Schering Plough, Novartis, Bristol Myers Squibb, Regeneron, Iovance Biotherapeutics, Alkermes, Ultimovacs, Genesis Drug Discovery and Development, and Sun Pharma. He has received research funding to the institution (Moffitt Cancer Center) from Neogene Therapeutics, Turnstone Bio, and Skyline Diagnostics, not related to this research. Jonathan S Zager has advisory board relationships with or has received fees from Merit Medical, Merck, Novartis, Philogen, Castle Biosciences, Pfizer, and Sun Pharma. He also received research funding from Amgen, Delcath Systems, Philogen, Provectus, and Novartis. He serves on the medical advisory board for Delcath Systems. John E Mullinax is an inventor on intellectual property that Moffitt Cancer Center has licensed to Iovance Biotherapeutics. He participates in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech that are not related to this research. He has received research support that is not related to this research from the following entities: NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation. Dr Mullinax has received consulting fees from Merit Medical, Lyell Therapeutics, and Iovance Biotherapeutics. The remaining authors have no relevant conflicts of interest to disclose.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu